These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16610366)

  • 1. Hsp90 inhibitors in the clinic.
    Pacey S; Banerji U; Judson I; Workman P
    Handb Exp Pharmacol; 2006; (172):331-58. PubMed ID: 16610366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
    Ivy PS; Schoenfeldt M
    Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
    [No Abstract]   [Full Text] [Related]  

  • 3. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A; Boehm MF; Burrows FJ
    Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP; Toft DO; Ames MM; Erlichman C
    Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 as a therapeutic target in prostate cancer.
    Solit DB; Scher HI; Rosen N
    Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-AAG: mechanisms of antitumour activity.
    Konstantinopoulos PA; Papavassiliou AG
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1471-4. PubMed ID: 16307487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein and proteasome targeting agents.
    Takimoto CH; Diggikar S
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J; Whitesell L
    Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein inhibitor shows antitumor activity.
    Dunn FB
    J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
    Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
    Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L
    Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
    Maloney A; Workman P
    Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.
    Piper PW; Panaretou B; Millson SH; Truman A; Mollapour M; Pearl LH; Prodromou C
    Gene; 2003 Jan; 302(1-2):165-70. PubMed ID: 12527207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.